Results 211 to 220 of about 460,260 (336)

Enzyme replacement therapy and antibodies in late-onset Pompe disease

Molecular Genetics and Metabolism Reports, 2014
I. Schneider, M. Deschauer, F. Hanisch
doaj   +1 more source

Atrioventricular Block in a Pompe Disease Patient Receiving Enzyme Replacement Therapy. [PDF]

JACC Case Rep
Akagi K, Baba S, Matsuda K, Yoshida T, Hirata T, Yokoyama A, Yoneda F, Fukumura F, Kume E, Takita J.   +9 more
europepmc   +1 more source

Pancreatic enzyme replacement therapy

Suizo, 2017
Yusuke TANDO, Eri SATO, Shinji CHIKAZAWA, Atsufumi MATSUMOTO, Yuki MATSUHASHI, Miyuki YANAGIMACHI, Teruo NAKAMURA   +6 more
openaire   +2 more sources

Phase Engineering of Nanomaterials (PEN): Evolution, Current Challenges, and Future Opportunities

Advanced Materials, EarlyView.
This review summarizes the synthesis, phase transition, advanced characterization spanning ex situ to in situ and operando techniques, and diverse applications of phase engineering of nanomaterials (PEN). It further outlines key challenges and future opportunities, such as phase stability, architecture control, and artificial intelligence (AI)‐driven ...
Ye Chen, Zhanxi Fan, Jingjie Ge, Qiyuan He, Zhuangchai Lai, Jiawei Liu, Chaoliang Tan, Hua Zhang   +7 more
wiley   +1 more source

Long-Term Enzyme Replacement Therapy and Renal Outcomes in Fabry Disease: A Systematic Review and Meta-Analysis. [PDF]

Biomedicines
Chen CY, Li CT, Lin CJ, Shih HM, Liu SJ, Sun FJ, Wu CJ.   +6 more
europepmc   +1 more source

Lipid Nanoparticle Co‐Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy

Advanced Materials, EarlyView.
Co‐encapsulation of p53 mRNA and the small molecule ciclopirox within a lipid nanoparticle yields an all‐in‐one chemoimmunotherapy for oral squamous cell carcinoma. The platform engages caspase‐driven apoptosis in cancer cells while repolarizing tumor‐associated macrophages, achieving tumor reduction in both p53‐susceptible and p53‐resistant models and
Marshall S. Padilla, Jacqueline J. Li, Qunzhou Zhang, Korey Patwari, Shihong Shi, Hannah M. Yamagata, Ryann A. Joseph, Briyanna N. Hymms, Sridatta V. Teerdhala, Emily Fitzgerald, Ori Z. Chalom, Kushol Gupta, Mohamad‐Gabriel Alameh, Drew Weissman, Anh D. Le, Michael J. Mitchell   +15 more
wiley   +1 more source

How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases? [PDF]

Orphanet J Rare Dis
Spataro F, Solimando AG, Desantis V, Vacca A, Di Girolamo A, Ria R.   +5 more
europepmc   +1 more source

Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges

Journal of Bone and Mineral Research, 2017
M. Whyte
semanticscholar   +1 more source

Sonoenzymatically Triggered Cascading Degradation of Bioresorbable Materials for On‐Demand Transient Triboelectric Implants

Advanced Materials, EarlyView.
Our SEA strategy provides an efficient and biosafe approach for the on‐demand removal of implanted bioresorbable materials through cascading degradation that couples ultrasound‐triggered rapid mechanical disintegration with subsequent enzymatic degradation.
Jinsong Kim, Dong‐Min Lee, Youngwook Chung, Byung‐Joon Park, Hyeon Mo, Jong Won Seon, Han‐Yup Yum, Bosung Kim, Byung‐Ok Choi, Sang‐Woo Kim   +9 more
wiley   +1 more source

Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results. [PDF]

J Inherit Metab Dis
Wasserstein MP, Hollak CE, Barbato A, Gallagher RC, Giugliani R, Guelbert NB, Hennermann JB, Ikezoe T, Lachmann R, Lidove O, Mabe P, Mengel E, Scarpa M, Senates E, Tchan M, Thurberg BL, Villarrubia J, Armstrong NM, Bhushan S, Kim Y, Kumar M.   +20 more
europepmc   +1 more source